Filing Details

Accession Number:
0001209191-17-054555
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-10-02 15:44:43
Reporting Period:
2017-10-02
Accepted Time:
2017-10-02 15:44:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1533040 Rxi Pharmaceuticals Corp RXII () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1285648 Geert Cauwenbergh C/O Rxi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough MA 01752
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2017-10-02 2,700 $0.44 135,283 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2017-10-02 200 $0.46 135,483 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2017-10-02 7,100 $0.45 142,583 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.0001 Par Value 4,500 Indirect By spouse
Common Stock, $0.0001 Par Value 450 Indirect By son
Footnotes
  1. Represents shares held by the Reporting Person's son. The Reporting Person disclaims beneficial ownership of such shares and this report shall not constitute an admission ofbeneficial ownership.